We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.33 | 0.67% | 49.34 | 49.35 | 49.38 | 284 | 11:30:19 |
From May 2019 to May 2024
By Jason Chow
PARIS--French drug maker Sanofi SA (SNY) said on Friday that it gained approval from Japanese authorities to market its new Toujeo diabetes drug.
Japan's Ministry of Health, Labor and Welfare granted authorization for the insulin drug under the trade name Lantus XR. The same drug is sold under the Toujeo name in the U.S. and Europe.
Sanofi has long hoped that Toujeo would eventually replace the revenue generated by its older Lantus diabetes drug. Lantus accounted for almost a fifth of the company's total sales in the most recent quarter but has been under pricing pressure in the crucial U.S. market. Lantus is also set to go off patent later this year.
Toujeo is currently available in the U.S., Germany, Denmark and the Netherlands. The company expects more countries to approve the drug "in the coming months."
Diabetes is one of the world's biggest drug markets, generating more than $38 billion in yearly sales, according to EvaluatePharma.
-Write Jason Chow at jason.chow@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
